Active substance
Results for the substance satralizumab
1 result
About this active substance
Satralizumab is a humanized monoclonal antibody used in the treatment of neuromyelitis optica (NMO) and its spectrum disorders (NMOSD), a rare autoimmune disease affecting the optic nerves and spinal cord. It works by blocking the interleukin-6 (IL-6) receptor, reducing inflammation and autoimmune activity that contribute to neurological damage.
Satralizumab is administered as a subcutaneous injection, typically once every four weeks after an initial loading phase. It is commonly used in patients who are seropositive for anti-aquaporin-4 antibodies (AQP4-IgG), which are associated with a higher risk of relapses.
Common side effects include headache, fatigue, injection site reactions, and upper respiratory tract infections. In rare cases, severe adverse reactions such as serious infections or allergic responses may occur. Regular monitoring is essential to ensure the safety and efficacy of the treatment.
Satralizumab represents an innovative therapeutic option for patients with NMOSD, helping to reduce relapse frequency and improve their quality of life.
Satralizumab is administered as a subcutaneous injection, typically once every four weeks after an initial loading phase. It is commonly used in patients who are seropositive for anti-aquaporin-4 antibodies (AQP4-IgG), which are associated with a higher risk of relapses.
Common side effects include headache, fatigue, injection site reactions, and upper respiratory tract infections. In rare cases, severe adverse reactions such as serious infections or allergic responses may occur. Regular monitoring is essential to ensure the safety and efficacy of the treatment.
Satralizumab represents an innovative therapeutic option for patients with NMOSD, helping to reduce relapse frequency and improve their quality of life.